For research use only. Not for therapeutic Use.
Evifacotrep, a short transient receptor potential channel 5 and 4 (TRPC5/TRPC4) antagonist (WO2020061162, compound 100), can be used for the research of neurological diseases. Evifacotrep targets to TRPC5/TRPC4 with IC50s ≤50 nM[1].
Evifacotrep (1 μM; 24 h) inhibits cell growth in ICLN-1694 cells(HEK-TRExhTRPC4)[1].
Evifacotrep (30 mg/kg; sc; once daily or twice daily for 10 days) results in reduced urinary albumin excretion on following injury with puromycinaminonucleoside (PAN)[1].
| Catalog Number | I027164 |
| CAS Number | 2413739-88-3 |
| Synonyms | 5-chloro-4-[4-[4-fluoro-2-(trifluoromethyl)phenoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-7-yl]-1H-pyridazin-6-one |
| Molecular Formula | C18H12ClF4N5O2 |
| Purity | ≥95% |
| InChI | InChI=1S/C18H12ClF4N5O2/c19-15-13(6-26-27-16(15)29)28-4-3-10-12(7-28)24-8-25-17(10)30-14-2-1-9(20)5-11(14)18(21,22)23/h1-2,5-6,8H,3-4,7H2,(H,27,29) |
| InChIKey | IQFZADSTVFSHDX-UHFFFAOYSA-N |
| SMILES | C1CN(CC2=C1C(=NC=N2)OC3=C(C=C(C=C3)F)C(F)(F)F)C4=C(C(=O)NN=C4)Cl |
| Reference | [1]. WO2020061162 |
